BACKGROUND: Lipoatrophy modestly improves when the thymidine analogue nucleoside reverse transcriptase inhibitor (tNRTI) is removed. In vitro, uridine (NucleomaxX(®); Pharma Nord, Vojens, Denmark) reversed tNRTImitochondrial toxicity. METHODS: All patients had lipoatrophy on a tNRTI-containing regimen with HIV RNA<400 copies/ml. A randomized 48-week study switched patients from tNRTI to tenofovir (TDF) or added uridine (continuing tNRTI). End points were changes in limb fat (DEXA), subcutaneous abdominal fat mitochondrial DNA (mtDNA) and mitochondrial RNA (mtRNA), inflammation markers (soluble tumour necrosis factor receptors, high-sensitivity C reactive protein [hsCRP], interleukin-6 [IL-6], soluble vascular cell adhesion molecule 1), bone mineral density (BMD) of the hip and spine, HIV-1 RNA, CD4(+) T-cells and fasting metabolic parameters. RESULTS:Fifty patients were enrolled (n=24 TDF switch; n=26 uridine); median age 48 years; 54% white; 86% male; limb fat 4,494 g. Baseline characteristics were similar between groups. In the NucleomaxX(®) arm, mtRNA increased (all P<0.001), hsCRP and IL-6 increased (both P=0.02), whereas fat mtDNA decreased without changes in limb fat. In the TDF-switch arm, fat mtDNA and inflammation markers did not change; however, significant increases in mtRNAs (P<0.001), limb fat (409 g; IQR -59-1,155) and CD4(+) T-cell count (P=0.03), and decreases in total and hip BMD (median -3.3%; IQR -5.1-0; P=0.005) were observed. Between-group changes were significant for fat mtDNA, hsCRP, IL-6, limb fat and hip BMD. No correlation was found between changes in limb fat and those of fat mtRNA, inflammation markers or protease inhibitor duration. CONCLUSIONS: In HIV lipoatrophy, NucleomaxX(®) improved mtRNA, but worsened inflammation markers and fat mtDNA without changes in limb fat. Switching from a tNRTI to TDF for 48 weeks increased limb fat and fat mtRNA. Large decreases in total and hip BMD were seen after TDF switch. ClinicalTrials.gov identifier: NCT00119379.
RCT Entities:
BACKGROUND: Lipoatrophy modestly improves when the thymidine analogue nucleoside reverse transcriptase inhibitor (tNRTI) is removed. In vitro, uridine (NucleomaxX(®); Pharma Nord, Vojens, Denmark) reversed tNRTI mitochondrial toxicity. METHODS: All patients had lipoatrophy on a tNRTI-containing regimen with HIV RNA<400 copies/ml. A randomized 48-week study switched patients from tNRTI to tenofovir (TDF) or added uridine (continuing tNRTI). End points were changes in limb fat (DEXA), subcutaneous abdominal fat mitochondrial DNA (mtDNA) and mitochondrial RNA (mtRNA), inflammation markers (soluble tumour necrosis factor receptors, high-sensitivity C reactive protein [hsCRP], interleukin-6 [IL-6], soluble vascular cell adhesion molecule 1), bone mineral density (BMD) of the hip and spine, HIV-1 RNA, CD4(+) T-cells and fasting metabolic parameters. RESULTS: Fifty patients were enrolled (n=24 TDF switch; n=26 uridine); median age 48 years; 54% white; 86% male; limb fat 4,494 g. Baseline characteristics were similar between groups. In the NucleomaxX(®) arm, mtRNA increased (all P<0.001), hsCRP and IL-6 increased (both P=0.02), whereas fat mtDNA decreased without changes in limb fat. In the TDF-switch arm, fat mtDNA and inflammation markers did not change; however, significant increases in mtRNAs (P<0.001), limb fat (409 g; IQR -59-1,155) and CD4(+) T-cell count (P=0.03), and decreases in total and hip BMD (median -3.3%; IQR -5.1-0; P=0.005) were observed. Between-group changes were significant for fat mtDNA, hsCRP, IL-6, limb fat and hip BMD. No correlation was found between changes in limb fat and those of fat mtRNA, inflammation markers or protease inhibitor duration. CONCLUSIONS: In HIV lipoatrophy, NucleomaxX(®) improved mtRNA, but worsened inflammation markers and fat mtDNA without changes in limb fat. Switching from a tNRTI to TDF for 48 weeks increased limb fat and fat mtRNA. Large decreases in total and hip BMD were seen after TDF switch. ClinicalTrials.gov identifier: NCT00119379.
Authors: David Nolan; Emma Hammond; Annalise Martin; Louise Taylor; Susan Herrmann; Elizabeth McKinnon; Cecily Metcalf; Bruce Latham; Simon Mallal Journal: AIDS Date: 2003-06-13 Impact factor: 4.177
Authors: Graeme J Moyle; Caroline A Sabin; Jonathan Cartledge; Margaret Johnson; Edmund Wilkins; Duncan Churchill; Philip Hay; Ade Fakoya; Maurice Murphy; George Scullard; Clifford Leen; Geraldine Reilly Journal: AIDS Date: 2006-10-24 Impact factor: 4.177
Authors: Grace A McComsey; Ulrich A Walker; Chakra B Budhathoki; Zhaohui Su; Judith S Currier; Lisa Kosmiski; Linda G Naini; Stéphannie Charles; Kathy Medvik; Judith A Aberg Journal: AIDS Date: 2010-10-23 Impact factor: 4.177
Authors: Ana Milinkovic; Esteban Martinez; Sonia López; Elisa de Lazzari; Oscar Miró; Sergi Vidal; José L Blanco; Gloria Garrabou; Montserrat Laguno; Joan A Arnaiz; Agathe Leon; Maria Larrousse; Montserrat Lonca; Josep Mallolas; José M Gatell Journal: Antivir Ther Date: 2007
Authors: Grace A McComsey; Douglas J Ward; Siegrid M Hessenthaler; Michael G Sension; Peter Shalit; J Tyler Lonergan; Robin L Fisher; Vanessa C Williams; Jaime E Hernandez Journal: Clin Infect Dis Date: 2003-12-18 Impact factor: 9.079
Authors: Mariana Gerschenson; Courtney Kim; Baiba Berzins; Babafemi Taiwo; Daniel E Libutti; Julia Choi; Diana Chen; Jill Weinstein; Jessica Shore; Barbara da Silva; Elizabeth Belsey; Grace A McComsey; Robert L Murphy Journal: J Antimicrob Chemother Date: 2009-03-25 Impact factor: 5.758
Authors: Maile Y Karris; Sonia Jain; Tyler R C Day; Josué Pérez-Santiago; Miguel Goicoechea; Michael P Dubé; Xiaoying Sun; Celsa Spina; Eric S Daar; Richard H Haubrich; Sheldon Morris Journal: HIV Clin Trials Date: 2017-01-30
Authors: Greg S Gojanovich; Denise L Jacobson; Jennifer Jao; Jonathan S Russell; Russell B Van Dyke; Daniel E Libutti; Tanvi S Sharma; Mitchell E Geffner; Mariana Gerschenson Journal: AIDS Res Hum Retroviruses Date: 2020-07-20 Impact factor: 2.205
Authors: Sri Masyeni; Erly Sintya; Dewi Megawati; Ni Made Hegard Sukmawati; Dewa Ga Budiyasa; Sri Agung Aryastuti; Siti Qamariyah Khairunisa; Igkn Arijana; N Nasronudin Journal: HIV AIDS (Auckl) Date: 2018-07-30